Article
The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin.
Clinical immunology (Orlando, Fla.) - 1 Jul 2003
Glas J, Török H P, Simperl C, König A, Martin K, Schmidt F, Schaefer M, Schiemann U, Folwaczny C
Abstract excerpt
Unlike in HIV, homozygosity for a 32-bp deletion (Delta 32) of the chemokine receptor 5 (CCR5) gene was recently described in increased frequency in patients with chronic hepatitis C (HCV). Thus, it was speculated that this mutation might be relevant for disease susceptibility and influence the response to antiviral therapy. The present study sought to confirm the association between HCV and the Delta 32 mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.